Outperform was Maintained on Natera (NASDAQ:NTRA) by Baird; with $20 Target.

June 29, 2018 - By Alberto Lyles

Natera, Inc. (NASDAQ:NTRA) Corporate Logo

Reiterated Natera (NASDAQ:NTRA) Rating.

After Baird’s $20 PT was sent to investors on Thursday, 28 June, Natera (NASDAQ:NTRA) would indicate 4.22 % upside potential.

Natera, Inc. (NASDAQ:NTRA) Ratings Coverage

A total of 4 analysts rate Natera (NASDAQ:NTRA) as follows: 4 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:NTRA) has 8 ratings reports on Jun 29, 2018 according to StockzIntelligence. On Thursday, June 28 the rating was maintained by Robert W. Baird with “Outperform”. In Wednesday, March 14 report Robert W. Baird maintained it with “Buy” rating and $17.0 target. In Friday, June 22 report Craig Hallum maintained the stock with “Buy” rating. On Monday, June 25 the rating was maintained by Canaccord Genuity with “Buy”. On Wednesday, March 14 the firm has “Buy” rating by Canaccord Genuity given. On Monday, June 25 the stock has “Overweight” rating by Morgan Stanley. On Wednesday, May 9 the firm earned “Overweight” rating by Morgan Stanley.

NTRA reached $19.19 during the last trading session after $0.22 change.Natera, Inc. has volume of 209,466 shares. Since June 29, 2017 NTRA has risen 12.60% and is uptrending. NTRA outperformed the S&P500 by 0.03%.

Natera, Inc. (NASDAQ:NTRA) is expected to report earnings on August, 14., according to Zacks. Analysts predict $-0.53 EPS. That’s $0.01 down or 1.92 % from 2017’s earnings of $-0.52. After $-0.61 EPS was revealed previous quarter, analysts now see EPS growth of -13.11 % for Natera, Inc..

Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services.The firm is valued at $1.05 billion. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.Last it reported negative earnings. The firm also provides Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father.

For more Natera, Inc. (NASDAQ:NTRA) news released briefly go to: Benzinga.com, Benzinga.com, Benzinga.com, Benzinga.com or Fool.com. The titles are as follows: “42 Biggest Movers From Yesterday” released on June 28, 2018, “50 Biggest Movers From Friday” on June 25, 2018, “44 Biggest Movers From Yesterday” with a publish date: June 26, 2018, “40 Stocks Moving In Wednesday’s Mid-Day Session” and the last “Why Natera Inc. Is Rising Today” with publication date: June 25, 2018.

Natera, Inc. (NASDAQ:NTRA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: